Isavuconazole, also knownc as BAL4815 and RO 0094815, is a triazole antifungal drug. Its prodrug, isavuconazonium sulfate (BAL8557), was granted approval by the U.S. Food and Drug Administration (FDA) on March 6, 2015 for the treatment of invasive candidiasis. Isavuconazole works by inhibiting lanosterol 14 alpha-demethylase, the enzyme responsible for converting lanosterol to ergosterol by demethylation. The resulting depletion of ergosterol and build up of lanosterol compromise the structure of the fungal cell membrane. Mammalian cells are resistant to demethylation inhibition by azoles, making the drug effects specific to fungi.
Properties:
Density: 1.38
Boiling Point: 678ºC at 760 mmHg
Flash Point: 363.8ºC
Fungal Inhibitors Related Products:
Miconazole nitrate; AN2718; Terbinafine HCl; Liranaftate; Fenticonazole Nitrate; Amorolfine HCl; Tioconazole; Butoconazole nitrate; Tavaborole; Cicloheximide; Luliconazole; Efinaconazole; Micafungin sodium; Micafungin; Butenafine hydrochloride